Last reviewed · How we verify
Deucrictibant high dose
Deucrictibant is a bradykinin receptor 2 antagonist.
Deucrictibant is a bradykinin receptor 2 antagonist. Used for Hypertension.
At a glance
| Generic name | Deucrictibant high dose |
|---|---|
| Sponsor | Pharvaris Netherlands B.V. |
| Drug class | Bradykinin receptor antagonist |
| Target | B2 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
Deucrictibant works by blocking the action of bradykinin at its receptor, which is involved in blood pressure regulation. This leads to vasodilation and a decrease in blood pressure. Deucrictibant is being investigated for its potential to treat hypertension.
Approved indications
- Hypertension
Common side effects
- Hypotension
Key clinical trials
- Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema (PHASE2, PHASE3)
- Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema (PHASE2)
- Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |